Sugi Predict

Sugi Predict / Targets / AHSA1

AHSA1

Activator of 90 kDa heat shock protein ATPase homolog 1 · O95433 · AHSA1 on Sugi Atlas →

39 patent compounds predicted against AHSA1, 21 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1346518 SCHEMBL1346518 0.55 1/20
SCHEMBL1347532 SCHEMBL1347532 0.53 1/20
SCHEMBL17799175 SCHEMBL17799175 0.53 1/20
SCHEMBL4540149 SCHEMBL4540149 0.48 1/20
SCHEMBL6813680 SCHEMBL6813680 0.47 1/20
SCHEMBL4539932 SCHEMBL4539932 0.47 1/20
SCHEMBL4540612 SCHEMBL4540612 0.46 1/20
SCHEMBL13604102 SCHEMBL13604102 0.46 1/20
SCHEMBL23658940 SCHEMBL23658940 0.45 1/20
SCHEMBL24236807 SCHEMBL24236807 0.45 1/20
SCHEMBL4543981 SCHEMBL4543981 0.45 1/20
SCHEMBL1127087 SCHEMBL1127087 0.45 1/20
SCHEMBL28442983 SCHEMBL28442983 0.45 1/20
SCHEMBL6052408 SCHEMBL6052408 0.44 1/20
SCHEMBL4543666 SCHEMBL4543666 0.42 1/20
SCHEMBL1127977 SCHEMBL1127977 0.42 1/20
SCHEMBL23658937 SCHEMBL23658937 0.42 1/20
SCHEMBL31492047 SCHEMBL31492047 0.42 1/20
SCHEMBL19684405 SCHEMBL19684405 0.42 1/20
SCHEMBL4541873 SCHEMBL4541873 0.41 1/20

Clinical trials — most relevant to AHSA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease PHASE2COMPLETED
Targeting the Tumor Microenvironment in R/M SCCHN PHASE1/PHASE2UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies PHASE1WITHDRAWN
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma PHASE1COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma PHASE1COMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC nanCOMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Acute Passive Heating in Healthy Older Adults nanCOMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Spastic Paraplegia - Centers of Excellence Research Network nanRECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AHSA1 binder may also engage these)

ProteinNameSimilarity
Q8BK64 — 1.000 Q8BK64 →
Q8N9S3 — 0.994 Q8N9S3 →
Q9P782 — 0.989 Q9P782 →
A6QQC0 — 0.982 A6QQC0 →
P31669 — 0.979 P31669 →
A2YQ56 — 0.977 A2YQ56 →
Q12449 — 0.977 Q12449 →
Q4R4I6 — 0.977 Q4R4I6 →
P93648 — 0.977 P93648 →
Q9CQN1 — 0.976 Q9CQN1 →
ELP1 Elongator complex protein 1 0.976 landscape →
Q55DB6 — 0.976 Q55DB6 →
Q9TRY0 — 0.976 Q9TRY0 →
Q5ZJM3 — 0.976 Q5ZJM3 →
O94436 — 0.976 O94436 →
P11035 — 0.976 P11035 →
A0A4P8DJE6 — 0.976 A0A4P8DJE6 →
Q5U2T9 — 0.976 Q5U2T9 →
Q9W3C1 — 0.975 Q9W3C1 →
Q9QXY6 — 0.975 Q9QXY6 →
P27008 — 0.975 P27008 →
P34685 — 0.975 P34685 →
P34686 — 0.975 P34686 →
Q9CYT6 — 0.975 Q9CYT6 →
Q9W2N0 — 0.975 Q9W2N0 →
P27124 — 0.975 P27124 →
F4J8C6 — 0.975 F4J8C6 →
Q84WW3 — 0.974 Q84WW3 →
G5ECQ8 — 0.974 G5ECQ8 →
Q11208 — 0.974 Q11208 →